Calprotectin: A protein related to cardiovascular risk in adult patients with obstructive sleep apnea

Cytokine

Volumn 61, Issue 3, 2013, Pages 917-923

  Cholidou, Kyriaki G ^a   Kostakis, Ioannis D ^a   Manali, Effrosyni D ^a   Perrea, Despina ^a   Margeli, Alexandra ^b   Vougas, Konstantinos ^c   Markozannes, Evangelos ^a   Koulouris, Nikolaos ^a   Alchanatis, Manos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Calprotectin; Cholesterol; Hs CRP; Obstructive sleep apnea; S100A8 A9 complex

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CHEMOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGEN; TRIACYLGLYCEROL;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; OXYGEN SATURATION; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLEEP DISORDERED BREATHING; SLEEP TIME; TRANSTHORACIC ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LIPIDS; POLYSOMNOGRAPHY; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; SPIROMETRY;

EID: 84875378418     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.014     Document Type: Article

References (40)

1. Quercioli A., Mach F., Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 2010, 14:261-269.
2. Arnaud C., Dematteis M., Pepin J.L., Baguet J.P., Lévy P. Obstructive sleep apnea, immuno-inflammation, and atherosclerosis. Semin Immunopathol 2009, 31:113-125.
3. Lévy P., Pépin J.L., Arnaud C., Baguet J.P., Dematteis M., Mach F. Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis 2009, 51:400-410.
4. Lavie L. Oxidative stress and inflammation in OSA. Eur Respir Mon 2010, 50:360-380.
5. Kent B.D., McNicholas W.T. Overview of basic mechanisms of cardiovascular disease in OSA. Eur Respir Mon 2010, 50:340-359.
6. Jelic S., Le Jemtel T.H. Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. Trends Cardiovasc Med 2008, 18:253-260.
7. Lavie L., Dyugovskaya L., Polyakov A. Biology of peripheral blood cells in obstructive sleep apnea - the tip of the iceberg. Arch Physiol Biochem 2008, 114:244-254.
8. Ryan S., Taylor C.T., McNicholas W.T. Systemic inflammation a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnea syndrome. Thorax 2009, 64:631-636.
9. Miller M., Zhan M., Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors. The third national health and nutrition examination survey. Arch Intern Med 2005, 165:2063-2068.
10. Shamsuzzaman A.S., Winnicki M., Lanfranchi P., Wolk R., Kara T., Accurso V., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002, 105:2462-2464.
11. Can M., Açikgöz S., Mungan G., Bayraktaroĝlu T., Koçak E., Güven B., et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006, 129:233-237.
12. Kostakis I.D., Cholidou K.G., Kallianidis K., Perrea D., Antsaklis A. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol 2010, 151:3-9.
13. Inaba H., Hokamura K., Nakano K., Nomura R., Katayama K., Nakajima A., et al. Upregulation of S100 calcium-binding protein A9 is required for induction of smooth muscle cell proliferation by a periodontal pathogen. FEBS Lett 2009, 583:128-134.
14. Boyd J.H., Kan B., Roberts H., Wang Y., Walley K.R. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008, 102:1153-1154.
15. Altwegg L.A., Neidhart M., Hersberger M., Müller S., Eberli F.R., Corti R., et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007, 28:941-948.
16. Croce K. S100A8/A9 complex: more than just a biomarker of cardiovascular risk?. Circ J 2010, 74:626-627.
17. Croce K., Gao H., Wang Y., Mooroka T., Sakuma M., Shi C., et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009, 120:427-436.
18. Baumann M., Schmaderer C., Burkhardt K., Haller B., Heemann U., Dugi K., et al. MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest May 4 2011.
19. Kim J., Bhattacharjee R., Snow A.B., Capdevila O.S., Kheirandish-Gozal L., Gozal D. Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea. Eur Respir J 2010, 35:843-850.
20. Kim J., Lee S., Bhattacharjee R., Khalyfa A., Kheirandish-Gozal L., Gozal D. Leukocyte telomere length and plasma catestatin and myeloid-related protein8/14 concentrations in children with obstructive sleep apnea. Chest 2010, 138:91-99.
21. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
22. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
23. Vestbo J., Hurd S.S., Rodriguez-Roisin R. The 2011 Revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)-why and what?. Clin Respir J 2012, 6:208-214.
24. Iber C., Ancoli-Israel S., Chesson A., Quan S.F. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification 2007, American Academy of Sleep Medicine, Westchester (IL). 1st ed.
25. Stephens MA. Tests based on EDF statistics. In: D'Agostino RB, Stephens MA, editors. Goodness-of-Fit Techniques. New York: Marcel Dekker; 1986.
26. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2011. ISBN 3-900051-07-0. URL http://www.R-project.org/.
27. Polotsky V.Y., Savransky V., Bevans-Fonti S., Reinke C., Li J., Grigoryev D.N., et al. Intermittent and sustained hypoxia induce a similar gene expression profile in the human aortic endothelial cells. Physiol Genomics 2010, 41:306-314.
28. Taylor C.T. Interdependent roles for hypoxia inducible factor and nuclear factor-kappa B in hypoxic inflammation. J Physiol 2008, 586:4055-4059.
29. Viemann D., Strey A., Janning A., Jurk K., Klimmek K., Vogl T., et al. Myeloid-related proteins 8 and14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005, 105:2955-2962.
30. Oliver K.M., Garvey J.F., Ng C.T., Veale D.J., Fearon U., Cummins E.P., et al. Hypoxia activates NF-kappa B dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal 2009, 11:2057-2064.
31. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
32. Zouaoui Boudjeltia K., Van Meerhaeghe A., Doumit S., Guillaume M., Cauchie P., Brohée D., et al. Sleep apnoea-hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration 2006, 73:243-246.
33. Hayashi M., Fujimoto K., Urushibata K., Takamizawa A., Kinoshita O., Kubo K. Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome. Respirology 2006, 11:24-31.
34. Guven S.F., Turkkani M.H., Ciftci B., Ciftci T.U., Erdogan Y. The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep Breath 2012, 16:217-221.
35. Steiropoulos P., Tsara V., Nena E., Fitili C., Kataropoulou M., Froudarakis M., et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007, 132:843-851.
36. Yokoe T., Minoguchi K., Matsuo H., Oda N., Minoguchi H., Yoshino G., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129-1134.
37. Mermigkis C, Bouloukaki I, Mermigkis D, Kallergis E, Mavroudi E, Varouchakis G, et al. CRP evolution pattern in CPAP-treated obstructive sleep apnea patients. Does gender play a role? Sleep Breath; Sep 1 2011.
38. Averill M.M., Kerkhoff C., Bornfeldt K.E. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Throm Vasc Biol 2012, 32:223-229.
39. Ghavani S., Eshragi M., Ande S.R., Chazin W.J., Klonisch T., Halayko A.J., et al. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross talk between mitochondria and lysosomes that involves BNIP3. Cell Res 2010, 20:314-331.
40. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP polymorphism influences CRP levels: implication for the prediction of pathogenesis of coronary artery disease. Arterioscler Thromb Vasc Biol; 2003 [232063-2069].